Showing results (281-290 of 317) with videos related to

Sort By:
Pageof 32
Mayo Clinic Proceedings|June 6, 2018
Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical InformationAyalew Tefferi, Naseema Gangat, Mythri Mudireddy, et al.
Haematologica|May 4, 2019
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditionsPeter Valent, Attilio Orazi, Michael R Savona, et al.
Blood Advances|December 4, 2024
Single-cell multiomics reveal divergent effects of DNMT3A- and TET2-mutant clonal hematopoiesis in inflammatory responseWazim Mohammed Ismail, Jenna A Fernandez, Moritz Binder, et al.
Blood Cancer Journal|April 6, 2026
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patientsSaubia Fathima, Lior Rokach, Nour Ghosoun, et al.
Blood Cancer Journal|June 23, 2026
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myelomaBinoy Yohannan, Benjamin W Langworthy, Lindsey E Turner, et al.
American Journal of Hematology|July 18, 2026
Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive ChemotherapyAbiola Bolarinwa, Aref Al-Kali, Hassan B Alkhateeb, et al.
Blood|January 28, 2021
Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repairJithma P Abeykoon, Xiaosheng Wu, Kevin E Nowakowski, et al.
Oncotarget|April 21, 2017
Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to deliveryAlan H Bryce, Jan B Egan, Mitesh J Borad, et al.
Blood Advances|January 7, 2026
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopeniasTalha Badar, Ludovica Marando, Eric Latorre-Crespo, et al.
Cancer Discovery|August 27, 2024
RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal HematopoiesisNana Adjoa Ben-Crentsil, Wazim Mohammed Ismail, Maria E Balasis, et al.
Pageof 32